Biotech | July 06, 2025
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
InnoCell is the brand name for Mitsui Chemicals’ cell culture products and services
Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
The collaboration aims to enhance the accuracy of physics-based methods with AI models for optimising small molecule medicine discovery and development
Extended lab space for product development, customer demos, and training
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data
Star Health Insurance is modernising its claims ecosystem to be future-ready
Subscribe To Our Newsletter & Stay Updated
